Jun 2026 (Q2 FY26) — Aug 6, 2026
Trevi Therapeutics Q2 FY26 — Clinical Milestones Achieved, Strong Cash Runway
Read the full callTrevi Therapeutics (TRVI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Trevi Therapeutics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -17.8 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$12.11 +0.41% · +$0.05
Performance +18.8% 1Y
1Y: $10.19 on 14 Oct 2025 → $12.11. High $19.5 (7 Jul 2026), low $9.99 (23 Jan 2026).
- Previous close
- $12.06
- 52-week range
- $9.99 – $19.5
- One year
- +14.03%
Overview
- Symbol
- TRVI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Trevi Therapeutics earnings calls (TRVI)
Financials
What the filings say
Net profit, year on year: −45% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -14 | -12 | -11 | -14 | -14 | -10 | -15 | -21 |
| Other income | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 |
| Interest | 0 | 0 | — | 0 | 0 | 0 | — | — |
| Profit before tax | -13 | -11 | -10 | -12 | -12 | -8 | -13 | -18 |
| Tax rate | 0.2% | −0.1% | 0.1% | 0.2% | 0.1% | 0.2% | 0.1% | 0.1% |
| Net profit | -13 | -11 | -10 | -12 | -12 | -8 | -13 | -18 |
| EPS ($ per share) | -0.13 | — | -0.09 | -0.09 | -0.08 | — | -0.09 | -0.11 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -109 | -114 | -147 | -181 | -210 | -239 | -287 | -330 |
| Total liabilities | 120 | 5 | 20 | 21 | 16 | 7 | 11 | 10 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | — | — | — | — | 108 | 51 | 74 | 169 |
| Total assets | 11 | 60 | 47 | 38 | 123 | 89 | 111 | 193 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -18 | -23 | -29 | -29 | -28 | -32 | -38 | -42 |
| Cash from investing | -0 | -0 | -0 | — | -107 | 59 | -22 | -94 |
| Cash from financing | 4 | 73 | 17 | 21 | 111 | -8 | 61 | 121 |
| Net cash flow | -15 | 50 | -12 | -8 | -24 | 20 | 2 | -15 |
| Capital expenditure | -0 | -0 | -0 | — | -0 | -0 | -0 | -0 |
| Free cash flow | -18 | -23 | -29 | — | -28 | -32 | -38 | -42 |
Insider filings
7 filings between Dec 2, 2025 and Sep 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$595.8K
4 sales by 1 insider
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 3
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Heffernan Michael Thomas | — | $595.8K | Sep 15, 2026 |
Latest filings (29)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Heffernan Michael Thomas Director | Sale 10b5-1 plan | 18,321 | $276.5K |
| Sep 15, 2026 | Heffernan Michael Thomas Director | Sale 10b5-1 plan | 100 | $1.6K |
| Sep 15, 2026 | Heffernan Michael Thomas Director | Option exercise 10b5-1 plan | 21,052 | $70.1K |
| Sep 15, 2026 | Heffernan Michael Thomas Director | Option exercise 10b5-1 plan | 18,421 | $56.0K |
| Sep 15, 2026 | Heffernan Michael Thomas Director | Sale 10b5-1 plan | 20,952 | $316.2K |
| Sep 15, 2026 | Heffernan Michael Thomas Director | Sale 10b5-1 plan | 100 | $1.6K |
| Dec 2, 2025 | Galletta Christopher See Remarks | Option exercise | 4,225 | $2.2K |
| Mar 25, 2025 | SCIASCIA THOMAS Chief Scientific Officer | Option exercise | 2,631 | $3.8K |
| Mar 25, 2025 | SCIASCIA THOMAS Chief Scientific Officer | Sale | 2,631 | $17.4K |
| Mar 21, 2025 | GOOD JENNIFER L President & CEO | Option exercise | 5,263 | $7.5K |
| Mar 21, 2025 | GOOD JENNIFER L President & CEO | Sale | 5,263 | $34.6K |
| Mar 10, 2025 | Simon Farrell Chief Commercial Officer | Sale 10b5-1 plan | 76,963 | $517.8K |
| Mar 10, 2025 | Simon Farrell Chief Commercial Officer | Option exercise 10b5-1 plan | 17,500 | $56.2K |
| Mar 10, 2025 | Simon Farrell Chief Commercial Officer | Option exercise 10b5-1 plan | 63,813 | $249.5K |
| Mar 10, 2025 | Simon Farrell Chief Commercial Officer | Option exercise 10b5-1 plan | 31,250 | $16.0K |
| Mar 10, 2025 | Simon Farrell Chief Commercial Officer | Sale 10b5-1 plan | 4,350 | $31.1K |
| Jan 8, 2025 | Delfini Lisa Chief Financial Officer | Option exercise | 5,000 | $2.6K |
| Jan 7, 2025 | Delfini Lisa Chief Financial Officer | Option exercise | 1,000 | $511 |
| Dec 13, 2024 | Galletta Christopher See Remarks | Option exercise | 15,000 | $7.7K |
| Sep 9, 2024 | GOOD JENNIFER L President & CEO | Sale | 1,840 | $5.6K |
| Sep 9, 2024 | GOOD JENNIFER L President & CEO | Option exercise | 1,840 | $2.6K |
| Sep 6, 2024 | GOOD JENNIFER L President & CEO | Sale | 4,219 | $12.8K |
| Sep 6, 2024 | GOOD JENNIFER L President & CEO | Option exercise | 4,219 | $6.0K |
| Sep 5, 2024 | GOOD JENNIFER L President & CEO | Sale | 40,277 | $125.3K |
| Sep 5, 2024 | GOOD JENNIFER L President & CEO | Option exercise | 40,277 | $57.6K |
| Sep 4, 2024 | GOOD JENNIFER L President & CEO | Option exercise | 10,981 | $15.7K |
| Sep 4, 2024 | GOOD JENNIFER L President & CEO | Sale | 10,981 | $33.2K |
| Sep 3, 2024 | GOOD JENNIFER L President & CEO | Option exercise | 3,863 | $5.5K |
| Sep 3, 2024 | GOOD JENNIFER L President & CEO | Sale | 3,863 | $11.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Trevi Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Trevi Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading